The EBOVAC3 project aims to support an essential part of the remaining clinical and manufacturing activities required for the licensure of the two-dose vaccine regimen in the European Union and the United States.

Building on work carried out under the EBOVAC1 and EBOVAC2 projects, EBOVAC3 is running clinical trials to gather safety and immunogenicity data in infants in Sierra Leone and Guinea; as well as health care workers in an area affected by Ebola in the Democratic Republic of Congo (DRC). It will also follow up participants who received the vaccine regimen in the EBOVAC-Salone trial in Sierra Leone to assess the safety and immunogenicity of the regimen in the longer term.

In addition to the clinical trials, EBOVAC3 aims to characterise outbreak preparedness in Sierra Leone, Guinea and the DRC through social science research and mapping of the existing preparedness activities in each of the three countries.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2024 Ebovac | Terms and Conditions | WordPress development by Toast.